DiaMedica Therapeutics (DMAC) Long-Term Investments (2023 - 2025)
DiaMedica Therapeutics' (DMAC) quarterly Long-Term Investments came in at $1.0 million in Q1 2025, down 89.74% quarter-over-quarter from $9.7 million in Q3 2023.
Powered by 
Analysis
DiaMedica Therapeutics (DMAC) Long-Term Investments (2023 - 2025) Analysis & Trends
DiaMedica Therapeutics (DMAC) has reported Long-Term Investments for 2 consecutive years, with $1.0 million the latest figure, recorded in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 209.95 Bn | 195.96 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 180.35 Bn | 177.17 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.26 Bn | 124.41 Bn | 2.84 Bn | 5.79 Bn |
| 4 | Regeneron Pharmaceuticals | 82.62 Bn | 74.62 Bn | 3.93 Bn | 9.83 Bn |
| 5 | Argenx Se | 61.19 Bn | 56.00 Bn | 1.37 Bn | -4.00 Mn |
| 6 | Moderna | 53.61 Bn | 48.47 Bn | 52.00 Mn | 1.77 Bn |
| 7 | Alnylam Pharmaceuticals | 33.75 Bn | 30.44 Bn | 992.69 Mn | 22.17 Mn |
| 8 | Biogen | 31.58 Bn | 30.30 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.42 Bn | 29.42 Bn | 1.16 Mn | - |
| 10 | DiaMedica Therapeutics | 346.81 Mn | 346.81 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2025 | 1.00 Mn |
| Sep 30, 2023 | 9.75 Mn |
| Jun 30, 2023 | 20.30 Mn |